Epic Sciences to Present at World CDx Boston 2015

Print 02 September 2015

 

SAN DIEGO, Sept. 2, 2015 /PRNewswire/ -- Epic Sciences, Inc. ("Epic Sciences"), announced today that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the World CDx Boston 2015, taking place at the Hilton Boston Logan Airport, September 8 – 11, 2015.

Dr. Prahalad will give a presentation titled, "Matching The Spectrum of Cellular Heterogeneity to the Spectrum of Therapeutic Response in Cancer."

The details of the presentation are as follows:

Over the past several years, there has been a growing appreciation of cancer's heterogeneity – the genomic and cellular diversity that exists within each patient's cancer. Individual populations of these rare cells can develop resistance to therapies and continue to grow and evolve, resulting in metastatic cancers that are unresponsive to many standard of care treatments.  At World CDx, Dr. Prahalad will discuss how Epic Sciences' no cell left behind® technology can identify and characterize all sub-types of circulating tumor cells (CTCs) in the blood, a technical advantage enabling real-time insight into cancer heterogeneity that is necessary to improve drug development and optimize the clinical trials of targeted or combination therapies.

"In essence, cancer is not a disease of averages but a disease of multiple cell populations, each with its own unique genomic profile, that occur simultaneously in patients," said Murali Prahalad, Ph.D., President and CEO of Epic Sciences. "Because Epic Sciences' no cell left behind technology enables real-time detection of proteomic and genomic aberrations at the single cell level, we can identify those clones driving therapy resistance and provide a better understanding of drug response to optimize companion diagnostic development."

World CDx Boston 2015 will bring together drug, diagnostic, and technology developers from target identification to launch of drug-CDx combinations to share latest clinical trial results and technological advancements, with the goal to accelerate personalized healthcare products to market. In recognition of the growing importance of liquid biopsy in cancer diagnostics, this year's agenda includes a liquid biopsy stream for the first time.

About Epic Sciences

Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences' mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic Sciences' no cell left behind® technology will help match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, the company partners with leading pharmaceutical companies and major cancer centers around the world. Epic Sciences' goal is to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.

Further information is available on the company's website, www.epicsciences.com.

any's website, www.epicsciences.com. 

Return